Your browser doesn't support javascript.
loading
Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles.
Wang, Lin; Quine, Skyler; Frickenstein, Alex N; Lee, Michael; Yang, Wen; Sheth, Vinit M; Bourlon, Margaret D; He, Yuxin; Lyu, Shanxin; Garcia-Contreras, Lucila; Zhao, Yan D; Wilhelm, Stefan.
Afiliación
  • Wang L; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, 73019, USA.
  • Quine S; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, 73019, USA.
  • Frickenstein AN; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, 73019, USA.
  • Lee M; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, 73019, USA.
  • Yang W; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, 73019, USA.
  • Sheth VM; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, 73019, USA.
  • Bourlon MD; College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73117, USA.
  • He Y; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, 73019, USA.
  • Lyu S; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, 73019, USA.
  • Garcia-Contreras L; College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73117, USA.
  • Zhao YD; Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73012, USA.
  • Wilhelm S; Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, USA.
Adv Funct Mater ; 34(8)2024 Feb 19.
Article en En | MEDLINE | ID: mdl-38828467
ABSTRACT
Most nanomedicines require efficient in vivo delivery to elicit diagnostic and therapeutic effects. However, en route to their intended tissues, systemically administered nanoparticles often encounter delivery barriers. To describe these barriers, we propose the term "nanoparticle blood removal pathways" (NBRP), which summarizes the interactions between nanoparticles and the body's various cell-dependent and cell-independent blood clearance mechanisms. We reviewed nanoparticle design and biological modulation strategies to mitigate nanoparticle-NBRP interactions. As these interactions affect nanoparticle delivery, we studied the preclinical literature from 2011-2021 and analyzed nanoparticle blood circulation and organ biodistribution data. Our findings revealed that nanoparticle surface chemistry affected the in vivo behavior more than other nanoparticle design parameters. Combinatory biological-PEG surface modification improved the blood area under the curve by ~418%, with a decrease in liver accumulation of up to 47%. A greater understanding of nanoparticle-NBRP interactions and associated delivery trends will provide new nanoparticle design and biological modulation strategies for safer, more effective, and more efficient nanomedicines.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Adv Funct Mater Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Adv Funct Mater Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania